GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1

BMC Cancer

Research

Edward J. Rice¹  Chinatsu Mukai¹  Ilissa M. Pipia¹  Scott A. Coonrod²  Brooke A. Marks²  Charles G. Danko²  Sachi Horibata³ 

[1] Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, USA;Department of Biomedical and Biological Sciences, College of Veterinary Medicine, Cornell University, Ithaca, USA;Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, USA;Department of Biomedical and Biological Sciences, College of Veterinary Medicine, Cornell University, Ithaca, USA;Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, USA;Precision Health Program, Michigan State University, East Lansing, MI, USA;Department of Pharmacology and Toxicology, College of Human Medicine, Michigan State University, East Lansing, MI, USA;

关键词: Breast cancer;    Estrogen receptor alpha;    Tamoxifen resistance;    GDNF;    RET signaling;    EGR1;    CCND1;    Positive feedback loop;   

DOI  :  10.1186/s12885-023-10559-1

 received in 2022-01-05, accepted in 2023-01-18,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundRearranged during transfection (RET) tyrosine kinase signaling has been previously implicated in endocrine resistant breast cancer, however the mechanism by which this signaling cascade promotes resistance is currently not well described. We recently reported that glial cell-derived neurotrophic factor (GDNF)-RET signaling appears to promote a positive feedback loop with the transcription factor early growth response 1 (EGR1). Here we investigate the mechanism behind this feedback loop and test the hypothesis that GDNF-RET signaling forms a regulatory loop with EGR1 to upregulate cyclin D1 (CCND1) transcription, leading to cell cycle progression and tamoxifen resistance.MethodsTo gain a better understanding of the GDNF-RET-EGR1 resistance mechanism, we studied the GDNF-EGR1 positive feedback loop and the role of GDNF and EGR1 in endocrine resistance by modulating their transcription levels using CRISPR-dCAS9 in tamoxifen sensitive (TamS) and tamoxifen resistant (TamR) MCF-7 cells. Additionally, we performed kinetic studies using recombinant GDNF (rGDNF) treatment of TamS cells. Finally, we performed cell proliferation assays using rGDNF, tamoxifen (TAM), and Palbociclib treatments in TamS cells. Statistical significance for qPCR and chromatin immunoprecipitation (ChIP)-qPCR experiments were determined using a student’s paired t-test and statistical significance for the cell viability assay was a one-way ANOVA.ResultsGDNF-RET signaling formed a positive feedback loop with EGR1 and also downregulated estrogen receptor 1 (ESR1) transcription. Upregulation of GDNF and EGR1 promoted tamoxifen resistance in TamS cells and downregulation of GDNF promoted tamoxifen sensitivity in TamR cells. Additionally, we show that rGDNF treatment activated GDNF-RET signaling in TamS cells, leading to recruitment of phospho-ELK-1 to the EGR1 promoter, upregulation of EGR1 mRNA and protein, binding of EGR1 to the GDNF and CCND1 promoters, increased GDNF protein expression, and subsequent upregulation of CCND1 mRNA levels. We also show that inhibition of cyclin D1 with Palbociclib, in the presence of rGDNF, decreases cell proliferation and resensitizes cells to TAM.ConclusionOutcomes from these studies support the hypotheses that GDNF-RET signaling forms a positive feedback loop with the transcription factor EGR1, and that GDNF-RET-EGR1 signaling promotes endocrine resistance via signaling to cyclin D1. Inhibition of components of this signaling pathway could lead to therapeutic insights into the treatment of endocrine resistant breast cancer.

【 授权许可】

CC BY   
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

【 图 表 】

Fig. 3

Fig. 2

Fig. 2

Fig. 1

Fig. 4

Fig. 5

40517_2023_248_Article_IEq41.gif

40517_2023_248_Article_IEq40.gif

40517_2023_248_Article_IEq37.gif

Fig. 1

40517_2023_248_Article_IEq35.gif

40517_2023_248_Article_IEq23.gif

40517_2023_248_Article_IEq22.gif

40517_2023_248_Article_IEq21.gif

40517_2023_248_Article_IEq20.gif

40517_2023_248_Article_IEq19.gif

40517_2023_248_Article_IEq14.gif

40517_2023_248_Article_IEq13.gif

40517_2023_248_Article_IEq11.gif

40517_2023_248_Article_IEq8.gif

40517_2023_248_Article_IEq5.gif

Fig. 5

Fig. 1

Fig. 1